Biotech Commercialization Pivot: Dyadic and Precigen Scale Post-R&D

The fourth quarter of 2025 represents a watershed moment for the mid-cap biotechnology sector, characterized by a decisive shift from speculative research and development toward tangible commercial execution. This transition is most evident in the performance of Dyadic International and Precigen, both of which have successfully navigated the 'valley of death' between clinical validation and market entry. For Dyadic, the maturation of its C1 protein production platform has culminated in the early 2026 commercial launch of recombinant albumin in partnership with ProLiant Health and Biologics. This move transforms Dyadic from a licensing-dependent entity into a product-driven company with recurring profit-sharing revenue streams. The strategic focus on animal-free recombinant proteins, such as DNase I and transferrin, positions the company to capitalize on the growing demand for high-purity, non-animal derived components in the pharmaceutical and cell culture markets.

Precigen’s trajectory offers a parallel narrative of commercial scaling. The launch of Papzimius for adult recurrent respiratory papillomatosis (RRP) has already begun to reshape the company’s financial profile. After recording initial shipments in November 2025, Precigen saw its fiscal Q4 revenue jump to $3.4 million, with management projecting a massive leap to over $18 million in Q1 2026. This rapid ramp-up is supported by an aggressive market access strategy that has secured coverage for approximately 90% of U.S. insured lives, totaling 215 million people. The shift in Precigen’s spending—a 22% decrease in R&D offset by a nearly 70% increase in SG&A—is a textbook example of a biotech firm reallocating resources to support a high-stakes product launch. The broad FDA label for Papzimius, which includes no restrictions based on prior surgeries, provides a significant competitive advantage in the orphan drug space.

“

After recording initial shipments in November 2025, Precigen saw its fiscal Q4 revenue jump to $3.4 million, with management projecting a massive leap to over $18 million in Q1 2026.

While biotech firms focus on product launches, the infrastructure supporting patient access is seeing its own explosive growth. Paysign’s performance in 2025 highlights the increasing complexity and scale of the patient affordability market. With a 168% increase in revenue from its patient affordability segment, Paysign is benefiting from the pharmaceutical industry's desperate need for sophisticated co-pay and financial assistance management. The company now services 6 of the top 10 U.S. pharmaceutical manufacturers, processing claims that grew by 79% year-over-year. This growth is not merely a volume play; it is a technology play. Paysign’s platform saved clients over $325 million in 2025 by mitigating the impact of co-pay maximizer programs, demonstrating how Health IT solutions are becoming indispensable to drug manufacturers' bottom lines.